BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 16796930)

  • 1. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
    Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
    Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.
    Damiano AM; Pastores GM; Ware JE
    Qual Life Res; 1998 Jul; 7(5):373-86. PubMed ID: 9691718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
    Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
    Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.
    de Verteuil R; Imamura M; Zhu S; Glazener C; Fraser C; Munro N; Hutchison J; Grant A; Coyle D; Coyle K; Vale L
    Health Technol Assess; 2008 Jun; 12(26):iii-iv, ix-223. PubMed ID: 18513467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
    Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
    Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
    Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
    Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
    Wright M; Grieve R; Roberts J; Main J; Thomas HC;
    Health Technol Assess; 2006 Jul; 10(21):1-113, iii. PubMed ID: 16750059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.